PTJ
VOR icon

Paul Tudor Jones’s Vor Biopharma VOR Stock Holding History

Paul Tudor Jones’s Portfolio VOR Stock Details VOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$361K Sell
19,620
-132,951
-87% -$2.01M ﹤0.01% 3014
2026
Q1 		$2.72M Sell
152,571
-15,102
-9% -$213K 0.01% 1628
2025
Q4 		$2.19M Buy
+167,673
New +$3.12M ﹤0.01% 1744

Other funds holding VOR

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return

Paul Tudor Jones's VOR Position: Q2 2026 in Review

Paul Tudor Jones reduced its Vor Biopharma (VOR) stake by 87% in Q2 2026, selling an estimated $2.01M and leaving 19,620 shares worth $361K. The position accounts for ﹤0.01% of the portfolio, ranked #3014.

Paul Tudor Jones first reported a position in VOR in Q4 2025 and has held it in 3 quarters since. The position peaked at $2.72M in Q1 2026. 101 funds tracked by Wall St. Rank hold VOR as of Q2 2026.

  • Paul Tudor Jones held 19,620 shares of Vor Biopharma worth $361K as of Q2 2026.
  • Paul Tudor Jones sold 132,951 Vor Biopharma shares in Q2 2026, an estimated $2.01M.
  • Vor Biopharma made up ﹤0.01% of Paul Tudor Jones's portfolio in Q2 2026, its #3014 holding.
  • Paul Tudor Jones first reported a position in Vor Biopharma in Q4 2025 and has held it in 3 quarters since.
  • Paul Tudor Jones's Vor Biopharma position peaked at $2.72M in Q1 2026.
  • 101 funds tracked by Wall St. Rank held Vor Biopharma as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.